acut
respiratori
infect
ari
lead
caus
death
among
children
age
five
kill
four
million
peopl
per
year
account
global
burden
diseas
infect
often
result
pneumonia
singl
largest
infecti
caus
death
children
worldwid
kill
estim
children
age
five
ari
caus
virus
bacteria
fungi
avail
improv
diagnost
tool
led
identif
recent
year
virus
increasingli
frequent
caus
pneumonia
previou
work
group
other
found
respiratori
syncyti
viru
rsv
season
influenza
infa
enteroviru
ev
adenoviru
ad
predomin
pathogen
children
ari
adenoviru
type
preval
serotyp
ad
caus
ari
recent
year
adenoviru
type
also
caus
sever
pneumonia
death
children
adult
worldwid
effect
medicin
sever
viral
infect
gener
support
care
current
clinic
option
new
treatment
infect
desper
need
one
potenti
therapeut
option
passiv
immunotherapi
convalesc
plasma
hyperimmun
intraven
immunoglobulin
hivig
previou
work
suggest
approach
might
effect
treatment
infect
spanish
infa
avian
infa
pandem
infa
sar
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
among
other
howev
studi
report
use
approach
preval
viral
pathogen
infect
common
virus
lower
fatal
rate
caus
virus
list
caus
larg
number
sever
ari
sari
even
death
worldwid
everi
year
passiv
immunotherapi
import
screen
convalesc
plasma
prepar
hivig
convalesc
serum
high
titer
neutral
antibodi
nab
intraven
immunoglobulin
ivig
produc
larg
pool
healthi
volunt
unknown
nab
titer
use
clinic
prevent
treat
bacteri
viru
infect
hivig
vaccineimmun
donor
use
clinic
prevent
treat
specif
viru
infect
rabiesviru
hbv
given
high
infect
rate
childhood
virus
caus
ari
may
high
titer
nab
pathogen
adult
popul
therefor
ivig
healthi
blood
volunt
may
suitabl
sourc
convalesc
plasma
howev
report
describ
neutral
activ
specif
respiratori
virus
support
hypothesi
therefor
present
studi
investig
preval
serum
titer
nab
main
virus
caus
ari
includ
rsv
season
infa
ev
enteroviru
coxsackieviru
ad
well
rare
viru
caus
sever
epidem
outbreak
recent
year
healthi
adult
southern
china
also
evalu
nab
titer
virus
commerci
avail
ivig
discuss
need
prepar
hivig
convalesc
serum
serum
sampl
healthi
donor
collect
random
dongguan
children
hospit
dongguan
southern
china
donor
rang
age
year
old
sex
ratio
without
patient
identifi
research
involv
human
particip
approv
ethic
committe
affili
first
hospit
guangzhou
medic
univers
inform
consent
obtain
volunt
total
ten
bottl
human
immunoglobulin
intraven
inject
igg
protein
concentr
mgml
ivig
five
product
lot
use
studi
produc
guangdong
shuanglin
biopharmaci
co
ltd
januari
octob
plasma
collect
healthi
donor
ivig
dilut
dulbecco
modifi
eagl
medium
dmem
gibco
china
use
follow
viru
strain
use
neutral
assay
human
strain
genebank
enteroviru
type
strain
genebank
coxsacki
viru
strain
genebank
human
respiratori
syncyti
viru
strain
long
rsv
atcc
genebank
infa
strain
atcc
human
strain
genbank
kindli
provid
lin
chen
guangzhou
medic
univers
guangzhou
china
nab
respiratori
virus
human
serum
sampl
commerci
avail
ivig
sampl
quantit
detect
standard
vitro
microneutr
test
appropri
cell
type
brief
human
embryon
kidney
hek
cell
had
vero
cell
cell
rsv
mdck
cell
infa
seed
densiti
cell
per
well
plate
cultur
hour
concurr
tissu
cultur
infecti
dose
tcid
virus
mix
equal
volum
seriallydilut
human
serum
ivig
hour
mixtur
adsorb
onto
correspond
cell
incub
hour
titer
triplic
well
read
highest
dilut
sera
inhibit
viru
growth
without
visibl
cytopath
effect
cpe
comparison
seropreval
differ
group
evalu
use
pearson
binari
variabl
fisher
exact
method
appropri
statist
analys
comput
spss
version
spss
inc
chicago
il
usa
analys
p
valu
less
regard
signific
first
want
evalu
seropreval
healthi
adult
nab
common
respiratori
virus
shown
figur
incub
hr
typic
cpe
could
seen
cell
infect
rsv
infa
collect
serum
sampl
healthi
donor
perform
microneutr
assay
measur
titer
nab
sever
respiratori
virus
shown
figur
high
proport
sampl
healthi
adult
donor
neg
nab
five
virus
highest
proport
sampl
nab
titer
shown
tabl
comprehens
analys
perform
frequenc
histogram
drawn
illustr
impact
age
respiratori
viru
infect
percentag
sampl
age
group
posit
nab
respect
demonstr
tabl
percentag
sampl
posit
nab
titer
increas
age
donor
p
test
virus
signific
differ
proport
sampl
posit
nab
age
group
figur
addit
signific
differ
proport
nab
titer
male
femal
test
virus
tabl
total
sampl
posit
nab
five
common
virus
test
rsv
infa
eighti
sampl
posit
nab
least
four
five
virus
sampl
least
three
next
want
assess
nab
titer
common
respiratori
virus
commerci
avail
ivig
total
ten
bottl
five
human
immunoglobulin
lot
intend
intraven
inject
assess
sampl
igg
protein
concentr
mgml
ivig
dilut
dmem
nab
titer
detect
standard
microneutr
test
shown
figur
ivig
differ
product
lot
titer
virus
may
possibl
treat
ari
use
convalesc
plasma
serum
ivig
contain
high
titer
nab
specif
pathogen
passiv
immunotherapi
mainli
use
convalesc
plasma
convalesc
serum
hivig
prepar
convalesc
sera
suggest
potenti
effect
method
prevent
treat
sever
viral
infect
method
use
treat
ari
caus
sarscov
merscov
howev
ari
children
mainli
caus
rsv
infa
ev
ad
therefor
passiv
immunotherapi
studi
potenti
treatment
ari
children
passiv
immunotherapi
screen
prepar
convalesc
plasma
serum
main
difficulti
gener
convalesc
plasma
prepar
donor
diagnos
patient
volunt
vaccin
high
titer
specif
antibodi
hivig
produc
mixtur
convalesc
plasma
differ
individu
report
seropreval
nab
titer
common
respiratori
virus
healthi
adult
donor
studi
pilot
success
attempt
screen
plasma
high
titer
nab
common
respiratori
virus
healthi
adult
donor
found
commerci
ivig
contain
high
titer
nab
rsv
infa
ev
ad
high
proport
healthi
adult
donor
found
nab
common
respiratori
virus
tabl
high
rate
vaccin
infect
infa
may
explain
find
highest
proport
nab
posit
sampl
viru
mani
posit
sampl
high
nab
titer
infa
season
infa
vaccin
use
china
howev
vaccin
use
ad
rsv
find
high
percentag
sampl
posit
virus
demonstr
high
infect
rate
virus
chines
popul
sizabl
proport
sampl
high
nab
titer
infa
although
less
abund
sampl
also
high
nab
titer
rsv
result
suggest
healthi
blood
volunt
may
suitabl
sourc
convalesc
plasma
use
treat
sari
prepar
blood
bank
specif
virus
clinic
sari
still
common
southern
china
especi
children
immunodefici
patient
current
case
sometim
treat
use
plasma
undetermin
nab
titer
gener
support
care
case
may
effect
use
plasma
high
nab
titer
resourc
relationship
nab
titer
respiratori
virus
therapeut
effect
could
studi
addit
blood
high
titer
nab
respiratori
virus
also
could
use
specif
screen
human
neutral
monoclon
antibodi
individu
virus
studi
use
infa
standard
strain
isol
year
ago
evalu
preval
nab
found
serum
sampl
high
nab
titer
result
could
explain
presenc
crossreact
nab
natur
infect
howev
due
high
variabl
influenza
viru
antigen
might
appropri
screen
plasma
use
recent
epidem
influenza
strain
percentag
sampl
posit
nab
titer
increas
age
p
demonstr
figur
tabl
nab
virus
signific
differ
posit
proport
age
group
year
trend
agre
previou
work
show
often
detect
adult
popul
contrast
rsv
mainli
detect
children
signific
differ
proport
posit
sampl
titer
nab
male
femal
test
virus
tabl
base
result
blood
male
femal
volunt
use
screen
nab
virus
hivig
prepar
convalesc
plasma
patient
specif
pathogen
infect
unlik
hivig
standard
ivig
produc
blood
healthi
donor
wide
use
clinic
prevent
infect
ivig
also
success
use
treat
cmv
infect
parvoviru
infect
hivig
use
treat
infect
sarscov
merscov
like
low
infect
rate
virus
popul
high
titer
nab
infa
figur
found
sampl
healthi
donor
suggest
figur
therefor
highdos
ivig
may
need
treat
infect
caus
virus
knowledg
studi
test
use
ivig
treat
infect
virus
result
suggest
treatment
investig
howev
highdos
ivig
use
children
may
caus
side
effect
allerg
reaction
commerci
ivig
expens
easi
understand
hivig
prepar
sera
high
titer
nab
specif
viru
would
much
higher
titer
nab
viru
could
use
lowdos
due
presenc
high
nab
virus
adult
hivig
could
prepar
screen
sera
high
titer
nab
person
medicin
may
econom
effect
treat
specif
respiratori
viru
infect
new
type
ad
recombin
caus
sever
infect
china
region
sinc
interest
find
low
proport
sampl
adult
donor
posit
nab
commerci
avail
ivig
high
nab
titer
viru
find
may
due
fact
commerci
produc
ivig
prepar
healthi
donor
came
larger
area
low
proport
sampl
donor
posit
nab
suggest
may
littl
protect
popul
southern
china
indic
area
frequent
survey
infect
high
titer
nab
ivig
suggest
ivig
may
potenti
effect
earli
treatment
infect
possibl
investig
convalesc
plasma
high
nab
titer
common
respiratori
virus
infa
rsv
screen
healthi
blood
volunt
establish
blood
bank
treat
sari
addit
commerci
ivig
high
titer
nab
infa
low
titer
nab
rsv
indic
may
necessari
prepar
hivig
sera
high
titer
nab
treat
specif
viru
infect
research
provid
use
data
develop
passiv
immunotherapi
sari
